Vaniprevir

Drug Profile

Vaniprevir

Alternative Names: MK-7009; Vanihep

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antivirals; Macrocyclic compounds; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 30 Sep 2014 Registered for Hepatitis C (Combination therapy) in Japan (PO) - First global approval
  • 31 Mar 2014 Merck & Co. completes a phase III trial for Hepatitis C (combination therapy, treatment naive) in Japan (NCT01370642)
  • 14 Jan 2014 Preregistration for Hepatitis C (combination therapy) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top